14.82
-0.07%
Close of 9 Nov 2026, in BRL
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Raia Drogasil S/A
Its shares trade on B3 under the ticker RADL3.SA. It has been listed since 20 October 2010. In the fiscal year to 31 December 2025, it reported revenue of BRL 44.25bn and net income of BRL 1.30bn. At that date it held total assets of BRL 25.47bn and shareholders' equity of BRL 7.32bn.
Raia Drogasil SA engages in the retail sale of medicine, perfumery, personal care and beauty products, cosmetics and dermocosmetics. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2010-10-20. The Company’s sales are carried out by over 860 stores, located in the states of Sao Paulo, Minas Gerais, Rio de Janeiro, Parana, Goias, Espirito Santo, Santa Catarina, Rio Grande do Sul, Bahia, Mato Grosso and Mato Grosso do Sul and in the Distrito Federal. The firm operates through a range of subsidiaries, such as Raia SA and 4-Bio Medicamentos SA.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Food & Staples Retailing
- Listed since
- 20 Oct 2010
- Employees
- 44,631
- Website
- rd.com.br ↗
Leadership
Pay as last reported
- Mr. Antonio PipponziChairman of the Board, since 2011
- Mr. Renato RaduanChief Executive Officer, Member of the Executive Board, since 2024
- Mr. Marco BonomiIndependent Vice Chairman of the Board
- Mr. Marcello De ZagottisChief Operating Officer, Member of the Executive Board
- Mr. Antonio CoelhoVice President - Finance and Administration, Member of the Executive Board, since 2019
- Ms. Maria de SouzaVice President - People, Culture and Sustainability, Member of the Executive Board
- Mr. Bruno PipponziVice President - Health Business, Member of the Executive Board
- Mr. Fernando VarelaVice President - Digital Transformation, Member of the Executive Board
- Mr. Flavio De Moraes CorreiaInvestor Relations Officer, Member of the Executive Board
- Ms. Melissa CabralVice President of Pharmacy Operations, Member of the Executive Board
- Ms. Juliana PaixaoCommercial Vice President, Member of the Executive Board
- Mr. Eugenio De ZagottisDirector, since 2011
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 93
- Social
- 90
- Governance
- 58
- Direct emissions (scope 1)
- 20,980.46 t
- Energy emissions (scope 2)
- 7,962.89 t
- Value chain emissions (scope 3)
- 561,951.33 t
- Women in the workforce
- 63%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Raia Drogasil SA is one of the largest pharmaceutical retail companies in Brazil, allowing them to benefit from economies of scale and pricing advantages.
- The company has a strong brand presence and a wide network of stores, providing convenience and accessibility to customers.
- Raia Drogasil SA has a diversified product portfolio, including prescription drugs, over-the-counter medicines, personal care products, and beauty items, catering to a broad customer base.
Weaknesses
- The company heavily relies on the Brazilian market, making it vulnerable to economic fluctuations and political instability in the country.
- Raia Drogasil SA faces intense competition in the pharmaceutical retail sector, both from traditional brick-and-mortar stores and online platforms.
- The company's profitability may be affected by regulatory changes in the healthcare industry, pricing pressures, and reimbursement policies.
Opportunities
- Raia Drogasil SA can capitalize on the growing demand for healthcare products and services in Brazil, driven by an aging population and increased health awareness.
- Expansion into e-commerce and digital channels can help the company reach a wider customer base and improve convenience for its customers.
- The company can explore partnerships with healthcare providers and insurance companies to enhance its services and differentiate itself from competitors.
Threats
- The ongoing COVID-19 pandemic and potential future health crises pose a threat to the company's operations, supply chain, and customer demand.
- Increased regulations in the pharmaceutical industry can impact Raia Drogasil SA's operations, requiring compliance with quality standards and pricing regulations.
- Changing consumer behavior, such as a shift towards online shopping and preference for generic medications, can pose threats to the company's market share and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.